engleski

Products of Advanced Glycation in Diabetes and Vascular Disease

Advanced glycation endproducts (AGE) and-AGE-antibodies in free and immune complex bound form (AGE-IC) were assayed in serum of diabetic (n=69) and nondiabetic patients (n=78) with coronary artery disease (CAD), and 47 controls matched for age and sex. A blocking ELISA was chosen to test immunoreactivity against AGE epitope(s), and competitive ELISA with polyclonal anti-AGE-antibodies was used to measure total AGE content. Soluble AGE-IC were detected by ELISA using an immunochemical bridge. Anti-AGE immunoreactivity was significantly (p<0.05) higher in diabetics than in controls. Although great dispersion of anti-AGE-antibody titre was observed in nondiabetic CAD patients, there was no significant difference from controls. Both, diabetic and nondiabetic CAD patients had higher amount of circulating AGE-IC than controls (p<0.01). Study patients showed positive correlatin between serum AGEs and AGE-IC (DM+CAD: r=0.3, p<0.01 ; CAD: r=0.26, p<0.01), whereas no correlation was recorded in controls. Circulating AGEs and anti-AGE antibodies in free or IC bound form were detected in serum of healthy subjects, and in higher amounts in both diabetic and nondiabetic CAD patients. It is possible that AGEs and anti-AGE IgG are naturally occurring products under homeostatic control. In pathophysiological conditions, however, the intensified glycoxidation of biological proteins may surpass the rate of scavenging.

Diabetes; Coronary Artery Disease; Advanced Glycation; Antibody

nije evidentirano